8 completed, 1 withdrawn. 9 Phase 2, 2 Phase 1.
By phase and status
Follow ADX-629: new trials by email Literature Review of ADX-629 trials Research Report on ADX-629
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol Associated Hepatitis (Part 1) ADX-629 - Alcohol Hepatitis | Phase 2 | Completed | 4 | 2024-11-04 | 2026-06-03 |
A Clinical Trial in Subjects With Atopic Dermatitis (Part 1) ADX-629 (Open-label) - Atopic Dermatitis | Phase 2 | Completed | 8 | 2023-02-15 | 2026-11-10 |
ADX-629 Therapy for Sjogren-Larsson Syndrome ADX-629 - Sjogren-Larsson Syndrome | Phase 1 / Phase 2 | Completed | 8 | 2023-01-02 | 2026-05-05 |
Part 1 - A Clinical Trial in Patients With Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome ADX-629 - Nephrotic Syndrome | Phase 2 | Withdrawn | | 2023-01-01 | 2024-04-17 |
A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic Cough ADX-629, Placebo - Chronic Cough | Phase 2 | Completed | 51 | 2022-04-07 | 2025-02-28 |
A Clinical Trial to Evaluate the Safety and Efficacy of ADX-629 in in Subjects With Elevated Ethanol Levels ADX-629, Placebo - Ethanol Intoxication | Phase 1 / Phase 2 | Completed | 26 | 2021-11-15 | 2025-02-28 |
A Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Subjects With Plaque Psoriasis ADX-629 - Plaque Psoriasis | Phase 2 | Completed | 10 | 2021-05-07 | 2025-03-11 |
A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics for the Treatment of COVID-19. ADX-629, Placebo - Covid19 | Phase 2 | Completed | 11 | 2021-03-31 | 2025-02-17 |
A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety and Efficacy of Subjects With Mild Asthma Induced by the Bronchial Allergen Challenge (BAC) ADX-629, Placebo - Atopic Asthma | Phase 2 | Completed | 8 | 2021-01-09 | 2025-02-17 |
Conditions studied
COVID-19 (1) · Cerebral Palsy (1) · Chronic Cough (1) · Cough (1) · Dermatitis, Atopic (1) · Eczema (1) · Glomerulosclerosis, Focal Segmental (1) · Hepatitis, Alcoholic (1) · Ichthyosis (1) · Inflammation (1) · Intellectual Disability (1) · Muscle Spasticity (1) · Nephrosis, Lipoid (1) · Nephrotic Syndrome (1) · Renal Insufficiency, Chronic (1)
Sponsors
Aldeyra Therapeutics, Inc. (8) · University of Nebraska (1)
Countries
United States (8) · Canada (1)
Top investigators
William B Rizzo, MD (1)
Results publications
PMID 38724717, PMID 39513526